Agni-01NCT06060613
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 18 versions: 18 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 10 → 14 locations
- Minor Enrollment increased: 208 → 254 participants
- Eligibility criteria expanded, about 91 words
- Study description expanded, about 10 words
- Site details revised at 8 of 10 sites
- Minor Site details revised at 1 of 10 sitesv16
- Minor Study sites: 9 to 10v15
- Notable Primary and study completion pushed from Jun 30, 2028 to Jun 30, 2029
- Site contacts updated at 2 of 9 sites
- Eligibility criteria shortened, about 1 word
Show 12 earlier versionsHide 12 earlier versions
Notable Enrollment target: 52 to 208v13 Show 4 more changesShow less
- Primary endpoints: 2 to 3
- Eligibility criteria expanded, about 269 words
- Study description expanded, about 180 words
- Site contacts updated at 1 of 9 sites
- Notable Primary and study completion dates pushed to Jun 30, 2028
- Site contacts updated at 1 of 9 sites
- Minor Site contacts updated at 2 of 9 sitesv11
- Minor Study sites: 8 to 9
- Eligibility criteria expanded, about 11 words
- Minor Study sites: 7 to 8v9
- Minor Site contacts updated at 1 of 7 sitesv8
- Minor Study sites: 6 to 7
- Eligibility criteria expanded, about 45 words
- Minor Study sites: 4 to 6
- Eligibility criteria expanded, about 19 words
- Minor Study sites: 2 to 4v5
Notable Enrollment target: 32 to 52v4 Show 5 more changesShow less
- Eligibility criteria expanded, about 67 words
- Secondary endpoints: details revised at 1 of 2 entries
- Study sites revised (2)
- Study description shortened, about 2 words
- Study title shortened, about 4 words
- Minor Site details revised at 1 of 2 sitesv3
- Notable Trial status: Active, Not Recruiting to Recruiting
- Start date: Sep 22, 2023 to Oct 25, 2023
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence and nature of dose-limiting toxicities (DLTs)
Timeframe: 28 Days
The proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1
Timeframe: 2 years
Secondary (2)
The proportion of participants who have a confirmed CR or PR per RECIST v1.1
Incidence of AEs
Arms and interventions
Participants with advanced solid tumorsExperimental
Participants will receive conditioning therapy prior to administration of OBX-115 regimen.
Biologicals: OBX-115
Sites
14 sites in 2 countries
United States 13, Australia 1